Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2011 1
2012 1
2013 1
2014 3
2015 1
2016 2
2017 4
2018 4
2019 9
2020 6
2021 5
2022 5
2023 10
2024 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group. Heath PT, et al. N Engl J Med. 2021 Sep 23;385(13):1172-1183. doi: 10.1056/NEJMoa2107659. Epub 2021 Jun 30. N Engl J Med. 2021. PMID: 34192426 Free PMC article. Clinical Trial.
BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M
BACKGROUND: Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute r …
Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages.
Bonelli S, Geeraerts X, Bolli E, Keirsse J, Kiss M, Pombo Antunes AR, Van Damme H, De Vlaminck K, Movahedi K, Laoui D, Raes G, Van Ginderachter JA. Bonelli S, et al. FEBS J. 2018 Feb;285(4):777-787. doi: 10.1111/febs.14202. Epub 2017 Sep 6. FEBS J. 2018. PMID: 28834216 Free article. Review.
Hence, a multitude of approaches are currently pursued to intervene with TAM's protumor activities, the most advanced of which being a blockade of macrophage-colony stimulating factor (M-CSF)/M-CSF receptor (M-CSFR) signaling. M-CSFR signaling largely …
Hence, a multitude of approaches are currently pursued to intervene with TAM's protumor activities, the most advanced of which being a block …
Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting.
Erreni M, D'Autilia F, Avigni R, Bolli E, Arnouk SM, Movahedi K, Debie P, Anselmo A, Parente R, Vincke C, van Leeuwen FWB, Allavena P, Garlanda C, Mantovani A, Doni A, Hernot S, Van Ginderachter JA. Erreni M, et al. Theranostics. 2023 Jan 1;13(1):355-373. doi: 10.7150/thno.77560. eCollection 2023. Theranostics. 2023. PMID: 36593955 Free PMC article.
Results: Intravital microscopy demonstrated significant differences in the blood clearance rate and macrophage targeting kinetics of (m) and (biv)anti-MMR Nbs, both in tumoral and extra-tumoral tissue. Importantly, (m)anti-MMR Nbs are superior in reaching tissue mac …
Results: Intravital microscopy demonstrated significant differences in the blood clearance rate and macrophage targeting kinetics of (m
Mortality, perioperative complications and surgical timelines in hip fracture patients: Comparison of the Spanish with the non-Spanish Cohort of the HIP ATTACK-1 trial.
Guerra-Farfan E, Borges FK, Bhandari M, Garcia-Sanchez Y, Nuñez JH, Mestre-Torres J, Tomas-Hernandez J, Teixidor-Serra J, Balaguer-Castro M, Castillon P, Dealbert A, De Caso Rodriguez J, Aguado HJ, Guerado E, Popova E, Tonelli AC, Balasubramanian K, Vincent J, Harvey V, Kocaqi E, Slobogean G, Devereaux PJ; Hip Attack-1 Investigators. Guerra-Farfan E, et al. Injury. 2024 Nov;55(11):111827. doi: 10.1016/j.injury.2024.111827. Epub 2024 Aug 20. Injury. 2024. PMID: 39217648 Clinical Trial.
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions.
Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA. Laoui D, et al. Int J Dev Biol. 2011;55(7-9):861-7. doi: 10.1387/ijdb.113371dl. Int J Dev Biol. 2011. PMID: 22161841 Free article. Review.
On the other hand, anti-inflammatory mediators, including IL-4, IL-10, TGF-beta and M-CSF, induce diverse anti-inflammatory types of macrophages, known under the generic term M2. ...
On the other hand, anti-inflammatory mediators, including IL-4, IL-10, TGF-beta and M-CSF, induce diverse anti-inflammatory types of …
55 results